Zacks: Brokerages Expect Meridian Bioscience, Inc. (VIVO) to Post $0.16 Earnings Per Share

Brokerages predict that Meridian Bioscience, Inc. (NASDAQ:VIVO) will report earnings per share (EPS) of $0.16 for the current quarter, according to Zacks. Three analysts have issued estimates for Meridian Bioscience’s earnings. Meridian Bioscience posted earnings per share of $0.15 in the same quarter last year, which suggests a positive year-over-year growth rate of 6.7%. The company is scheduled to announce its next quarterly earnings report before the market opens on Thursday, November 8th.

According to Zacks, analysts expect that Meridian Bioscience will report full-year earnings of $0.70 per share for the current fiscal year, with EPS estimates ranging from $0.70 to $0.71. For the next year, analysts expect that the company will post earnings of $0.77 per share, with EPS estimates ranging from $0.74 to $0.81. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Meridian Bioscience.

Meridian Bioscience (NASDAQ:VIVO) last released its earnings results on Thursday, November 8th. The company reported $0.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.16 by $0.04. The company had revenue of $213.60 million during the quarter, compared to the consensus estimate of $51.11 million. Meridian Bioscience had a net margin of 11.49% and a return on equity of 16.97%. The company’s revenue was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.15 EPS.

A number of brokerages recently weighed in on VIVO. ValuEngine raised shares of Meridian Bioscience from a “hold” rating to a “buy” rating in a research report on Monday, October 29th. BidaskClub downgraded shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research report on Wednesday, July 11th. One investment analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $16.00.

In other Meridian Bioscience news, Director John Mcilwraith acquired 2,000 shares of the stock in a transaction that occurred on Friday, August 24th. The stock was acquired at an average price of $15.63 per share, with a total value of $31,260.00. Following the transaction, the director now directly owns 6,000 shares in the company, valued at $93,780. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 2.70% of the stock is owned by corporate insiders.

Large investors have recently made changes to their positions in the stock. Macquarie Group Ltd. bought a new stake in shares of Meridian Bioscience during the 2nd quarter valued at about $119,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of Meridian Bioscience during the 3rd quarter valued at about $151,000. Robecosam AG grew its position in shares of Meridian Bioscience by 194.3% during the 3rd quarter. Robecosam AG now owns 10,300 shares of the company’s stock valued at $153,000 after buying an additional 6,800 shares during the last quarter. Piedmont Investment Advisors LLC bought a new position in Meridian Bioscience in the 2nd quarter worth about $157,000. Finally, Itau Unibanco Holding S.A. bought a new position in Meridian Bioscience in the 2nd quarter worth about $162,000. 88.56% of the stock is owned by institutional investors and hedge funds.

Shares of VIVO traded up $2.65 during midday trading on Friday, hitting $19.63. The company had a trading volume of 654,760 shares, compared to its average volume of 241,985. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.89 and a current ratio of 5.73. Meridian Bioscience has a 52 week low of $13.53 and a 52 week high of $19.84. The company has a market capitalization of $695.28 million, a P/E ratio of 29.30 and a beta of 0.54.

About Meridian Bioscience

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

See Also: Beta

Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with's FREE daily email newsletter.

Leave a Reply